The mixed analyst opinions on Pharvaris, with 2 somewhat bullish and 3 indifferent ratings, indicate uncertainty in the stock's short-term performance. The average 12-month price target of $14.0, a 15.15% decrease from the previous average, suggests that analysts have lowered their expectations for the stock. This may lead to a neutral short-term impact on the stock price.